Quince Therapeutics Reveals First Patient Dosed In Phase 3 Clinical Trial Of EryDex For Treatment Of Ataxia-Telangiectasia; This Pivotal Phase 3 Study Will Be Conducted Under A Special Protocol Assessment Agreement With The U.S. FDA
$QNCX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Quince Therapeutics Reveals First Patient Dosed In Phase 3 Clinical Trial Of EryDex For Treatment Of Ataxia-Telangiectasia; This Pivotal Phase 3 Study Will Be Conducted Under A Special Protocol Assessment Agreement With The U.S. FDA